Results 11 to 20 of about 48,129 (210)
Hemophilia A with reduced coagulation factor Ⅺ: a case report and literature review
Zhongguo shuxue zazhi, 2023 Objective To investigate the possible molecular pathogenesis of a child with hemophilia A accompanied by coagulation factor Ⅺ reduction by testing coagulation-related indicators and genotyping in the child and his family.
Jie WANG +8 more
doaj +1 more source
BMC Health Services Research, 2022 Background Hemophilia care in mainland China has been greatly improved since the establishment of the Hemophilia Treatment Center Collaborative Network of China (HTCCNC), and most of drugs for hemophilia have been covered by basic medical insurance ...
Zhengwei Huang +6 more
doaj +1 more source
Hematology, Transfusion and Cell Therapy, 2023 Objective: Factor X deficiency (FXd) is a rare coagulation disorder that can be either hereditary or acquired. Case report: We characterized patients with FXd and evaluated their bleeding patterns and treatment strategies. Methodology: This retrospective
Nigar Abdullayeva +3 more
doaj +1 more source
Hemophilia-related health problems reported in the PROBE questionnaire (N = 25).
, 2023 Hemophilia-related health problems reported in the PROBE questionnaire (N = 25).
Raul Gamarra (16503189) +9 more
core +1 more source
Chemical Chaperones Improve Protein Secretion and Rescue Mutant Factor VIII in Mice with Hemophilia A. [PDF]
, 2012 nefficient intracellular protein trafficking is a critical issue in the pathogenesis of a variety of diseases and in recombinant protein production.
Tonn, Torsten +29 more
core +1 more source
Current Situation and Prospect of Pharmacoeconomic Evaluation of Hemophilia in China
罕见病研究, 2022 In 2018, hemophilia, one of the first ones, entered into the catalogue of Rare Disease in China. However, drug accessibility and affordability have been the challenges for hemophilia patients.
LI Shunping, DOU Lei, FANG Yunhai
doaj +1 more source
Spontaneous bleeding in a patient with malignant lymphoma: A case of acquired hemophilia [PDF]
, 2000 Background: Acquired hemophilia is a rare condition which can be associated with lymphoproliferative disease. Case Report: Eleven yea rs after the diagnosis of immunocytoma had been made, a 72-year-old man developed a high-titer factor VIII inhibitor. At
Brack, N. +5 more
core +1 more source
MOLECULAR MECHANISMS OF INHIBITOR DEVELOPMENT IN HEMOPHILIA
Mediterranean Journal of Hematology and Infectious Diseases, 2020 The development of neutralizing antibodies in hemophilia is a serious complication of factor replacement therapy. These antibodies, also known as “inhibitors”, significantly increase morbidity within the hemophilia population and lower the quality of ...
Davide Matino +2 more
doaj +1 more source
Journal of Thrombosis and Haemostasis, 2010 Mild hemophilia A (HA), defined by clinical features and factor VIII coagulant activity (FVIII:C) between 0.05 and 0.40 IU mL(-1), is characteristically distinct from severe HA. Indeed, although the molecular characterization of mild HA has permitted the identification of specific underlying mutations, its clinical phenotype is strikingly different ...
Franchini M +2 more
openaire +2 more sources
, 2012 This book demonstrates the great efforts aimed at further improving the care of the hemophilia, which may bring further improvement in the quality of life of hemophilia persons and their ...
core +1 more source